Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 17/20 | 0.72 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | SNCA | P37840 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16623338 | 0.92 | APP (0.62) | APPSULT1A1MAPTKDM4ENPC1 | |
| SCHEMBL2244143 | 0.90 | APP (0.72) | APPSULT1A1MAPTKDM4ENPC1 | |
| SCHEMBL5423269 | 0.90 | APP (0.81) | APPSULT1A1MAPTKDM4ENPC1 | |
| SCHEMBL2923164 | 0.87 | APP (0.71) | APPSULT1A1MAPTKDM4ENPC1 | |
| SCHEMBL12422217 | 0.86 | MAPT (0.81) | APPMAPTKDM4ENPC1GLA | |
| SCHEMBL2036269 | 0.84 | APP (1.00) | APPSULT1A1MAPTKDM4ENPC1 | |
| SCHEMBL1572293 | 0.84 | APP (0.72) | APPSULT1A1MAPTKDM4ENPC1 | |
| SCHEMBL9238817 | 0.84 | APP (1.00) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL3237813 | 0.83 | APP (0.71) | APPSULT1A1MAPTKDM4ENPC1 | |
| SCHEMBL21752044 | 0.83 | APP (1.00) | APPSULT1A1MAPTGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| US-20180028694-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-02-01 | — | — | US | disclosed |
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | disclosed |
| US-20130084245-A1 | PET MONITORING OF A-BETA-DIRECTED IMMUNOTHERAPY | WYETH LLC (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130084245-A1 | PET MONITORING OF A-BETA-DIRECTED IMMUNOTHERAPY | WYETH LLC (US) | 2013-04-04 | — | — | US | disclosed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | disclosed |
| EP-2222160-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | Pharmaxis Ltd. (AU) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009066152-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | VAPA, SLC6A11, VAPB | APP 1634/4885SULT1A1 618/4885MAPT 2307/4885 |
| US-20130084245-A1 | PET MONITORING OF A-BETA-DIRECTED IMMUNOTHERAPY | APBA1, APP, BACE1 | APP 2/4885SULT1A1 4586/4885MAPT 8/4885 |
| US-20180028694-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | APP 1/4885SULT1A1 642/4885MAPT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.